Enveda Therapeutics, Inc.
Boulder, Colorado, United States · Biotechnology, Other
Enveda Biosciences is a biotechnology company building the first high-resolution chemical map of the natural world to tackle the toughest problems in drug discovery. Enveda’s platform is the world’s most advanced drug discovery search engine for dark chemical space, building on years of cutting-edge advancements at the intersection of metabolomics and machine learning. Complementing its breakthrou
Key facts
- Headquarters
- Boulder, Colorado, United States
- Employees
- 387
- Industries
- Biotechnology, Other
- Status
- Private
- Website
- enveda.com
- Company page
Recent activity at Enveda Therapeutics, Inc.
- : Enveda raises $311 million in Series E funding led by Catalio Capital Management to advance its AI-driven drug discovery efforts.
- : Enveda Appoints Christopher K. Porter as Senior Vice President, Clinical Operations
- : Enveda Appoints Nadeem Sarwar, Ph.D., MPharm, MPhil as Senior Vice President
- : Enveda Raises $150M Series D Funding to Reach Unicorn Status with the support of Premji Invest. The funds will enhance their clinical pipeline and accelerate development.
- : Enveda Appoints Jason Kim as Chief Financial Officer
- : Enveda raised $130M in a Series C funding led by Kinnevik and FPV to advance a pipeline of 10 development candidates.
- : Enveda Launches ENV-294, the First AI-Discovered Drug Candidate for Atopic Dermatitis into Clinical Trials
- : Enveda Biosciences Appoints José Trevejo M.D. Ph.D. as Chief Medical Officer and Head of Clinical Pipeline Strategy
- : Enveda secures $55 million in Series B extension to integrate ancient remedies with AI for drug discovery.
- : Enveda Therapeutics
Enveda Therapeutics, Inc. funding history
| Date | Round | Amount |
|---|---|---|
| Sep 2026 | Series E | $311.0M |
| Sep 2025 | Series D | $150.0M |
| Nov 2024 | Series C | $130.0M |
| Jun 2024 | Series B | $55.0M |
| Mar 2023 | Venture | $62.5M |
Leadership
- Viswa Colluru, CEO & Founder
- Ifra Saifi, Data Science Contractor
- Sunil Kakarla, Associate Director Operations
- Rohit Sharma, Director
- Xavier Valencia, SVP Ptl
- Christopher K. Porter, Senior Vice President
- Nadeem Sarwar, Ph.D., MPharm, MPhil, Senior Vice President
- Jason Kim, Chief Financial Officer
- August Allen, Chief Technology Officer
- José Trevejo M.D. Ph.D., Chief Medical Officer
Verified email and direct lines for Enveda Therapeutics, Inc.’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Employee benefit plans
Enveda Therapeutics, Inc. files 3 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Companies similar to Enveda Therapeutics, Inc.
- Integra Resources · Biotechnology, Other
- Venus Concept Inc. · Biotechnology, Other
- Nurix Therapeutics · Biotechnology, Other
- Lifecore Biomedical · Biotechnology, Other
- Pulmonx · Biotechnology, Other
About Enveda Therapeutics, Inc.: questions and answers
What does Enveda Therapeutics, Inc. do?
Enveda Biosciences is a biotechnology company building the first high-resolution chemical map of the natural world to tackle the toughest problems in drug discovery. Enveda’s platform is the world’s most advanced drug discovery search engine for dark chemical space, building on years of cutting-edge advancements at the intersection of metabolomics and machine learning. Complementing its breakthrou
Where is Enveda Therapeutics, Inc. headquartered?
Enveda Therapeutics, Inc. is headquartered in Boulder, Colorado, United States.
How many employees does Enveda Therapeutics, Inc. have?
Enveda Therapeutics, Inc. has about 387 employees.
Has Enveda Therapeutics, Inc. raised funding?
Yes. Fundz has recorded 5 funding events for Enveda Therapeutics, Inc.. The most recent, Series E of $311.0M, was in Sep 2026.
Who leads Enveda Therapeutics, Inc.?
Viswa Colluru is a CEO & Founder at Enveda Therapeutics, Inc..
What is the latest news on Enveda Therapeutics, Inc.?
On Sep 23, 2026, Enveda raises $311 million in Series E funding led by Catalio Capital Management to advance its AI-driven drug discovery efforts.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy